Comparing the current results to its competitors, Milestone Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Milestone Pharmaceuticals Inc 's competitors' average revenue growth of 14.08 %, achieved in the same quarter.
Milestone Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The competitive environment for etripamil includes pharmaceutical and biotechnology companies, academic institutions, and government agencies. Competition is based on the ability to complete clinical trials, secure regulatory approvals, and market drugs effectively. Key factors influencing competition are product differentiation in terms of efficacy, safety, tolerability, dosing convenience, price, coverage, and reimbursement. Many competitors possess greater financial, technical, and human resources, as well as more experience in drug discovery, development, regulatory approval, and commercialization. Competitors may develop cures or more effective treatments that could make current or future products non-competitive or obsolete. Currently, no approved drug or drug candidate in clinical development allows patients with PSVT to self-administer treatment to terminate PSVT episodes.
September 6, 2024
Milestone Pharmaceuticals Inc. (NASDAQ: MIST), a biopharmaceutical company dedicated to developing innovative cardiovascular medicines, has announced promising news regarding its licensing partner, Ji Xing Pharmaceuticals Ltd. On September 6, 2024, Milestone revealed positive topline results from a Phase 3 clinical study of etripamil nasal spray in paroxysmal supraventricular tachycardia (PSVT) conducted in China. This trial, which is significant for its multi-center, randomized, double-blind, and placebo-controlled design, offers new insights into the efficacy and safety of etripamil for patients afflicted by this condition. Details of the Phase 3 StudyThe recent clinical trial in China aimed to closely re...
May 29, 2024
FDA Accepts Milestone Pharmaceuticals’ New Drug Application for CARDAMYST Nasal Spray for PSVT Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYSTMONTREAL and CHARLOTTE, N.C., May 29, 2024 Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company committed to the innovation, development, and commercialization of unique cardiovascular therapies, proudly announced today that the United States Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray on May 26, 2024. CARDAMYST is Milestone s lead investigational product aimed at managing paroxysmal supraventricular tachycardia (PSVT), a c...
May 22, 2024
Montreal, Canada October 15, 2023 Milestone Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative cardiovascular therapies, is excited to announce a new partnership with Arrhythmia Alliance to spearhead efforts aimed at increasing awareness around Supraventricular Tachycardia (SVT). This collaboration marks a significant step in both organizations ongoing commitment to improving patient outcomes through education, research, and advocacy.SVT Awareness Day is scheduled to be held on Wednesday, June 5, 2024. The day will serve as a cornerstone for a series of initiatives that seek to inform the public about the nature, symptoms, and treatment options ...
April 8, 2024
In an exciting breakthrough for patients suffering from Paroxysmal Supraventricular Tachycardia (PSVT), Milestone Pharmaceuticals unveiled the results of their Etripamil data at The American College of Cardiology Annual Meeting. The study showcased the potential of Etripamil in enabling patients to self-manage their recurring PSVT episodes. Furthermore, these groundbreaking findings were also published in The Journal of the American College of Cardiology, emphasizing the clinical significance of this research. This article aims to outline the key facts from the study and assess their impact on Milestone Pharmaceuticals.1. Self-Management of Recurring PSVT:The Etripamil data presented at The American College ...
Publicly Traded Peers of Milestone Pharmaceuticals Inc
Actinium Pharmaceuticals Inc Share Performance
+31.68%
This Quarter
Actinium Pharmaceuticals Inc
Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.
Sources:
Milestone Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Milestone Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
